{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infections%2C+Respiratory+Syncytial+Virus&page=4",
    "query": {
      "condition": "Infections, Respiratory Syncytial Virus",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 201,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infections%2C+Respiratory+Syncytial+Virus&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infections%2C+Respiratory+Syncytial+Virus&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:51:49.764Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04126213",
      "title": "Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT 60 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV MAT 120 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 534,
      "start_date": "2019-11-05",
      "completion_date": "2021-05-14",
      "has_results": true,
      "last_update_posted_date": "2021-12-13",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04126213"
    },
    {
      "nct_id": "NCT04980391",
      "title": "A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "15 Years to 49 Years · Female only"
      },
      "enrollment_count": 384,
      "start_date": "2021-08-03",
      "completion_date": "2023-05-30",
      "has_results": true,
      "last_update_posted_date": "2025-04-20",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04980391"
    },
    {
      "nct_id": "NCT03596801",
      "title": "Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "RSV 6120/∆NS1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV 6120/F1/G2/∆NS1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "6 Months to 59 Months"
      },
      "enrollment_count": 60,
      "start_date": "2018-06-29",
      "completion_date": "2024-04-25",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03596801"
    },
    {
      "nct_id": "NCT07249320",
      "title": "Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "ABRYSVO",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 1,
      "start_date": "2025-12-01",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07249320"
    },
    {
      "nct_id": "NCT00100373",
      "title": "RSV Challenge in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Respiratory Infections, Acute",
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "RSV challenge material",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "21 Years to 40 Years"
      },
      "enrollment_count": 13,
      "start_date": "2004-09",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100373"
    },
    {
      "nct_id": "NCT04520659",
      "title": "Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "RSV LID/ΔM2-2/1030s",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "6 Months to 24 Months"
      },
      "enrollment_count": 81,
      "start_date": "2022-03-16",
      "completion_date": "2024-04-18",
      "has_results": true,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Rochester, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04520659"
    },
    {
      "nct_id": "NCT03959488",
      "title": "A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "MEDI8897",
          "type": "DRUG"
        },
        {
          "name": "Palivizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "0 Years to 1 Year"
      },
      "enrollment_count": 925,
      "start_date": "2019-07-30",
      "completion_date": "2023-01-20",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 30,
      "location_summary": "Anaheim, California • Long Beach, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        },
        {
          "city": "Paramount",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03959488"
    },
    {
      "nct_id": "NCT03624790",
      "title": "Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Administered to Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "rRSV A/Maryland/001/11",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 40,
      "start_date": "2018-07-31",
      "completion_date": "2024-10-24",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03624790"
    },
    {
      "nct_id": "NCT04227210",
      "title": "Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV vaccine MV-012-968 (dosage #1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV vaccine MV-012-968 (dosage #2)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Meissa Vaccines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-01-14",
      "completion_date": "2020-08-27",
      "has_results": false,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04227210"
    },
    {
      "nct_id": "NCT05169905",
      "title": "A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV MAT vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "dTpa vaccine",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "9 Years to 49 Years · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2022-02-02",
      "completion_date": "2022-08-03",
      "has_results": true,
      "last_update_posted_date": "2023-04-07",
      "last_synced_at": "2026-10-14T16:51:49.764Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Beaumont, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Beaumont",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05169905"
    }
  ]
}